✦ LIBER ✦

Peptide receptor radionuclide therapy with177Lu-DOTATATE: the IEO phase I-II study

✍ Scribed by Lisa Bodei; Marta Cremonesi; Chiara M. Grana; Nicola Fazio; Simona Iodice; Silvia M. Baio; Mirco Bartolomei; Dario Lombardo; Mahila E. Ferrari; Maddalena Sansovini; Marco Chinol; Giovanni Paganelli

Book ID: 105964509
Publisher: Springer
Year: 2011
Tongue: English
Weight: 374 KB
Volume: 38
Category: Article
ISSN: 0340-6997
DOI: 10.1007/s00259-011-1902-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term evaluation of renal toxicity a

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with90Y-DOTATOC and177Lu-DOTATATE: the role of associated risk factors

✍ Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M. Grana; M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 206 KB

Long-term evaluation of renal toxicity a

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with90Y-DOTATOC and177Lu-DOTATATE: the role of associated risk factors

✍ Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M. Grana; M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 37 KB

Repeated cycles of peptide receptor radi

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

✍ Dorota Pach; Anna Sowa-Staszczak; Jolanta Kunikowska; Leszek Królicki; Małgorzat 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 432 KB

Phase II Study of the Antibody Drug Conj

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy

✍ Burris, H. A.; Rugo, H. S.; Vukelja, S. J.; Vogel, C. L.; Borson, R. A.; Limenta 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 176 KB